On November 2, 2010, Hoffmann-La Roche Ltd., in consultation with Health Canada strengthened their warning regarding QT/PR prolongation and the need for ECG monitoring with ritonavir-boosted Invirase.
For more information: Click here to view the Health Canada advisory
The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below
